Strategies for clinical dose optimization of T cell-engaging therapies in oncology

References

• Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–18. doi:10.1158/1078-0432.CCR-14-1860.
   PubMed Web of Science ®Google Scholar
• Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85–96. doi:10.1038/s41577-021-00547-6.
   PubMed Web of Science ®Google Scholar
• Salvaris R, Ong J, Gregory GP. Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas. J Pers Med. 2021;11(5). doi:10.3390/jpm11050355.
   Web of Science ®Google Scholar
• Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):1–18. doi:10.1186/s13045-021-01084-4.
   PubMed Web of Science ®Google Scholar
• Fucà G, Spagnoletti A, Ambrosini M, de Braud F, Di Nicola M. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. ESMO Open. 2021;6(1):100046. doi:10.1016/j.esmoop.2020.100046.
   PubMed Web of Science ®Google Scholar
• Wu Y, Yi M, Zhu S, Wang H, Wu K. Recent advances and challenges of bispecific antibodies in solid tumors. Exp Hematol Oncol. 2021;10(1):1–14. doi:10.1186/s40164-021-00250-1.
   PubMed Web of Science ®Google Scholar
• Singh A, Dees S, Grewal IS. Overcoming the challenges associated with CD3+ T-cell redirection in cancer. Br J Cancer. 2021;124(6):1037–48. doi:10.1038/s41416-020-01225-5.
   PubMed Web of Science ®Google Scholar
• Arvedson T, Bailis JM, Britten CD, Klinger M, Nagorsen D, Coxon A, Egen JG, Martin F. Targeting solid tumors with bispecific T cell engager immune therapy. Annu Rev Cancer Biol. 2022;6:17–34. doi:10.1146/annurev-cancerbio-070620-104325.
   Google Scholar
• Long M, Mims AS, Li Z. Factors affecting the cancer immunotherapeutic efficacy of T cell bispecific antibodies and strategies for improvement. Immunol Invest. 2022:1–39. doi:10.1080/08820139.2022.2131569.
   PubMed Web of Science ®Google Scholar
• Stieglmaier J, Benjamin J, Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther. 2015;15(8):1093–99. doi:10.1517/14712598.2015.1041373.
   PubMed Web of Science ®Google Scholar
• You G, Won J, Lee Y, Moon D, Park Y, Lee SH, Lee S-W. Bispecific antibodies: a smart arsenal for cancer immunotherapies. Vaccines. 2021;9(7):724. doi:10.3390/vaccines9070724.
   Web of Science ®Google Scholar
• Arvedson T, Bailis JM, Urbig T, Stevens JL. Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies. Curr Opin Biotechnol. 2022;78:102799. doi:10.1016/j.copbio.2022.102799.
   PubMed Web of Science ®Google Scholar
• Chen W, Yang F, Wang C, Narula J, Pascua E, Ni I, Ding S, Deng X, Chu MLH, Pham A, et al. One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics. mAbs. 2021;13(1). doi:10.1080/19420862.2020.1871171
   Web of Science ®Google Scholar
• Suurs FV, Lub-de Hooge MN, de Vries EGE, de Groot DJA. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019;201:103–19. doi:10.1016/j.pharmthera.2019.04.006.
   PubMed Web of Science ®Google Scholar
• Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM. The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126(14):3192–201. doi:10.1002/cncr.32909.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014:5. doi:10.3389/fimmu.2014.00520.
   PubMed Web of Science ®Google Scholar
• Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, Berkhout J. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. mAbs. 2018;10(5):751–64. doi:10.1080/19420862.2018.1462429.
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687–709. doi:10.1007/s10928-007-9065-1.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Tesar DB, Mukhyala K, Theil F-P, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21(12):2153–63. doi:10.1021/bc100261d.
   PubMed Web of Science ®Google Scholar
• Hu S, Datta-Mannan A, D’Argenio DZ. Physiologically based modeling to predict monoclonal antibody pharmacokinetics in humans from in vitro physiochemical properties. MAbs. 2022;14(1):2056944. doi:10.1080/19420862.2022.2056944.
   PubMed Web of Science ®Google Scholar
• Faroudi M, Utzny C, Salio M, Cerundolo V, Guiraud M, Müller S, Valitutti S. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci. 2003;100(24):14145–50. doi:10.1073/pnas.2334336100.
   PubMed Web of Science ®Google Scholar
• Li J, Piskol R, Ybarra R, Chen YJJ, Li J, Slaga D, Hristopoulos M, Clark R, Modrusan Z, Totpal K, et al. CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. 2019;11(508):1–13. doi:10.1126/scitranslmed.aax8861.
   Web of Science ®Google Scholar
• Germain RN, Stefanová I. THE DYNAMICS OF T CELL RECEPTOR SIGNALING: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol. 1999;17(1):467–522. doi:10.1146/annurev.immunol.17.1.467.
   PubMedGoogle Scholar
• Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, Clarke SC, Dang K, Harris KE, Iyer S, et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. mAbs. 2019;11(4):639–52. doi:10.1080/19420862.2019.1574521.
   PubMed Web of Science ®Google Scholar
• Vafa O, Trinklein ND. Perspective: designing T-cell engagers with better therapeutic windows. Front Oncol. 2020;10(April):1–7. doi:10.3389/fonc.2020.00446.
   PubMedGoogle Scholar
• Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, Ho J, Hristopoulos M, Clark R, Totpal K, et al. Relative target affinities of T-cell–dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther. 2018;17(4):776–85. doi:10.1158/1535-7163.MCT-17-0657.
   PubMed Web of Science ®Google Scholar
• Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavaré R, Ullman E, Mao S, Canova L, Sineshchekova O, et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep. 2021;11(1):1–17. doi:10.1038/s41598-021-93842-0.
   PubMed Web of Science ®Google Scholar
• Smith E, Olson K, Delfino F, DiLillo D, Kirshner J, Sineshchekova O, Zhang Q; Regeneron Pharmaceuticals, Inc. Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof. United States patent US 20200024356A1. 2020 January 23.
   Google Scholar
• Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154(October 2018):102–17. doi:10.1016/j.ymeth.2018.10.026.
   PubMedGoogle Scholar
• Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32. doi:10.1023/a:1014414520282.
   PubMed Web of Science ®Google Scholar
• Grimm HP. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn. 2009;36(5):407–20. doi:10.1007/s10928-009-9129-5.
   PubMed Web of Science ®Google Scholar
• Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn. 2010;37(4):323–46. doi:10.1007/s10928-010-9163-3.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Kim H, Yao Z, Szajek LP, Grasso L, Kim I, Paik CH. Tumor-shed antigen affects antibody tumor targeting: comparison of two 89 Zr-labeled antibodies directed against shed or nonshed antigens. Contrast Media Mol Imaging. 2018;2018:1–12. doi:10.1155/2018/2461257.
   Google Scholar
• Bacac M, Klein C, Umana P. CEA TCB: a novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5(8):1–3. doi:10.1080/2162402X.2016.1203498.
   Web of Science ®Google Scholar
• Petitcollin A, Bensalem A, Verdier M-C, Tron C, Lemaitre F, Paintaud G, Bellissant E, Ternant D. Modelling of the time-varying pharmacokinetics of therapeutic monoclonal antibodies: a literature review. Clin Pharmacokinet. 2020;59(1):37–49. doi:10.1007/s40262-019-00816-7.
   PubMed Web of Science ®Google Scholar
• Betts A, van der Graaf PH. Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin Pharmacol Ther. 2020;108(3):528–41. doi:10.1002/cpt.1961.
   PubMed Web of Science ®Google Scholar
• Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, De Groot AS. T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation–updated consensus and review 2020. Front Immunol. 2020:11. doi:10.3389/fimmu.2020.01301.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Penny HL, Kroenke MA, Bautista B, Hainline K, Chea LS, Parnes J, Mytych DT. Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology. J Immunother Cancer. 2022;10(4):e004225. doi:10.1136/jitc-2021-004225.
   PubMed Web of Science ®Google Scholar
• Cohen S, Chung S, Spiess C, Lundin V, Stefanich E, Laing ST, Clark V, Brumm J, Zhou Y, Huang C, et al. An integrated approach for characterizing immunogenic responses toward a bispecific antibody. MAbs. 2021;13(1). doi:10.1080/19420862.2021.1944017
   Web of Science ®Google Scholar
• Campagne O, Delmas A, Fouliard S, Chenel M, Chichili GR, Li H, Alderson R, Scherrmann J-M, Mager DE. Integrated pharmacokinetic/pharmacodynamic model of a bispecific CD3xCD123 DART molecule in nonhuman primates: evaluation of activity and impact of immunogenicity. Clin Cancer Res. 2018;24(11):2631–41. doi:10.1158/1078-0432.CCR-17-2265.
   PubMed Web of Science ®Google Scholar
• Leclercq G, Servera LA, Danilin S, Challier J, Steinhoff N, Bossen C, Odermatt A, Nicolini V, Umaña P, Klein C, et al. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. Oncoimmunology. 2022;11(1):2039432. doi:10.1080/2162402X.2022.2039432.
   PubMed Web of Science ®Google Scholar
• Saber H, Del Valle P, Ricks TK, Leighton JK. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regul Toxicol Pharmacol. 2017;90:144–52. doi:10.1016/j.yrtph.2017.09.001.
   PubMed Web of Science ®Google Scholar
• Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40(5):481–91. doi:10.1200/JCO.21.00931.
   PubMed Web of Science ®Google Scholar
• Holstein SA, Venkatakrishnan K, van der Graaf PH. Quantitative clinical pharmacology of CAR T‐cell therapy. Clin Pharmacol Ther. 2022;112(1):11–15. doi:10.1002/cpt.2631.
   PubMed Web of Science ®Google Scholar
• Yoneyama T, Kim M-S, Piatkov K, Wang H, Zhu AZX, Rubinstein R. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma. PLoS Comput Biol. 2022;18(7):e1009715. doi:10.1371/journal.pcbi.1009715.
   PubMed Web of Science ®Google Scholar
• Li -C-C, Bender B, Yin S, Li Z, Zhang C, Hernandez G, Kwan A, Sun L, Adamkewicz JI, Wang H, et al. Exposure-response analyses indicate a promising benefit/risk profile of mosunetuzumab in relapsed and refractory non-hodgkin lymphoma. Blood. 2019;134(Supplement_1):1285–1285. doi:10.1182/blood-2019-123961.
   Google Scholar
• Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002;100(6):690–97. doi:10.1002/ijc.10557.
   PubMed Web of Science ®Google Scholar
• Jiang X, Chen X, Carpenter TJ, Wang J, Zhou R, Davis HM, Heald DL, Wang W. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents. MAbs. 2018;10(6):876–89. doi:10.1080/19420862.2018.1480299.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Gudgeon CJ, Harrington KH, Dell’Aringa J, Newhall KJ, Means GD, Sinclair AM, Kischel R, Frankel SR, Walter RB. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4):554–61. doi:10.1182/blood-2013-09-527044.
   PubMed Web of Science ®Google Scholar
• Hipp S, Tai Y-T, Blanset D, Deegen P, Wahl J, Thomas O, Rattel B, Adam PJ, Anderson KC, Friedrich M. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31(8):1743–51. doi:10.1038/leu.2016.388.
   PubMed Web of Science ®Google Scholar
• Chen X, Haddish-Berhane N, Moore P, Clark T, Yang Y, Li H, Xuan D, Barton HA, Betts AM, Barletta F. Mechanistic projection of first-in-human dose for bispecific immunomodulatory P-cadherin LP-DART: an integrated PK/PD modeling approach. Clin Pharmacol Ther. 2016;100(3):232–41. doi:10.1002/cpt.393.
   PubMed Web of Science ®Google Scholar
• Van De Vyver A, Eigenmann M, Ovacik M, Pohl C, Herter S, Weinzierl T, Fauti T, Klein C, Lehr T, Bacac M, et al. A novel approach for quantifying the pharmacological activity of T-cell engagers utilizing in vitro time course experiments and streamlined data analysis. AAPS J. 2022;24(1):1–13. doi:10.1208/s12248-021-00637-2.
   Web of Science ®Google Scholar
• Dudal S, Hinton H, Giusti AM, Bacac M, Muller M, Fauti T, Colombetti S, Heckel T, Giroud N, Klein C, et al. Application of a MABEL approach for a T-cell-bispecific monoclonal antibody: CEA TCB. J Immunother. 2016;39(7):279–89. doi:10.1097/CJI.0000000000000132.
   PubMed Web of Science ®Google Scholar
• Frances N, Bacac M, Bray-French K, Christen F, Hinton H, Husar E, Quackenbush E, Schäfer M, Schick E, Van De Vyver A, et al. Novel in vivo and in vitro pharmacokinetic/pharmacodynamic-based human starting dose selection for glofitamab. J Pharm Sci. 2022;111(4):1208–18. doi:10.1016/j.xphs.2021.12.019.
   PubMed Web of Science ®Google Scholar
• Desnoyer A, Broutin S, Delahousse J, Maritaz C, Blondel L, Mir O, Chaput N, Paci A. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 2, immune checkpoint inhibitor antibodies. Eur J Cancer. 2020;128:119–28. doi:10.1016/j.ejca.2020.01.003.
   PubMed Web of Science ®Google Scholar
• Djebli N, Morcos PN, Jaminion F, Guerini E, Kratochwil NA, Justies N, Schick E, Kwan A, Humphrey K, Lundberg L, et al. Population pharmacokinetics and exposure-response analyses for glofitamab in relapsed/refractory B-cell non-hodgkin lymphoma (R/R NHL): confirmation of efficacy and CRS mitigation in patients with step-up dosing. Blood. 2020;136(Supplement 1):1–2. doi:10.1182/blood-2020-136311.
   PubMedGoogle Scholar
• Girgis S, Lin SXW, Pillarisetti K, Banerjee A, Stephenson T, Ma X, Shetty S, Yang T-Y, Hilder BW, Jiao Q, et al. Translational modeling predicts efficacious therapeutic dosing range of teclistamab for multiple myeloma. Target Oncol. 2022;(123456789). doi:10.1007/s11523-022-00893-y.
   Google Scholar
• Krishnan AY, Garfall AL, Mateos M-V, van de Donk NWCJ, Nahi H, San-Miguel F, Oriol J, Rosiñol A, Chari L, Bhutani A, et al. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). J Clin Oncol. 2021;39(15_suppl):8007–8007. doi:10.1200/JCO.2021.39.15_suppl.8007.
   Web of Science ®Google Scholar
• Berdeja JG, Krishnan AY, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos M-V, Minnema MC, Costa LJ, Verona R, et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). J Clin Oncol. 2021;39(15_suppl):8008–8008. doi:10.1200/JCO.2021.39.15_suppl.8008.
   Web of Science ®Google Scholar
• Bannerji R, Allan JN, Arnason JE, Brown JR, Advani RH, Barnes JA, Ansell SM, O’Brien SM, Chavez J, Duell J, et al. Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with Relapsed/Refractory (R/R) B-cell non-hodgkin lymphoma (B-NHL). Blood. 2019;134(Supplement_1):762–762. doi:10.1182/blood-2019-122451.
   Web of Science ®Google Scholar
• Zhu M, Olson K, Kirshner JR, Khaksar Toroghi M, Yan H, Haber L, Meagher C, Flink DM, Ambati SR, Davis JD, et al. Translational findings for odronextamab: from preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Clin Transl Sci. 2022;15(4):954–66. doi:10.1111/cts.13212.
   PubMed Web of Science ®Google Scholar
• van de Vyver AJ, Weinzierl T, Eigenmann MJ, Frances N, Herter S, Buser RB, Somandin J, Diggelmann S, Limani F, Lehr T, et al. Predicting tumor killing and t-cell activation by t-cell bispecific antibodies as a function of target expression: combining in vitro experiments with systems modeling. Mol Cancer Ther. 2021;20(2):357–66. doi:10.1158/1535-7163.MCT-20-0269.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29(2):57–61. doi:10.1016/j.tips.2007.11.004.
   PubMed Web of Science ®Google Scholar
• Betts A, Haddish-Berhane N, Shah DK, van der Graaf PH, Barletta F, King L, Clark T, Kamperschroer C, Root A, Hooper A, et al. A translational quantitative systems pharmacology model for CD3 bispecific molecules: application to quantify T cell-mediated tumor cell killing by P-cadherin LP DART®. AAPS J. 2019;21(4). doi:10.1208/s12248-019-0332-z
   Web of Science ®Google Scholar
• Lin L, Wille L, Betts A, Hua F, Hagen D, Park J, Apgar J, Burke J. Abstract A70: bridging nonclinical studies to clinical design using quantitative systems pharmacology model of T cell-engaging bispecifics. Cancer Immunol Res. 2020;8(3_Supplement):A70–A70. doi:10.1158/2326-6074.TUMIMM19-A70.
   PubMed Web of Science ®Google Scholar
• Kamperschroer C, Shenton J, Lebrec H, Leighton JK, Moore PA, Thomas O. Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics. J Immunotoxicol. 2020;17(1):67–85. doi:10.1080/1547691X.2020.1729902.
   PubMed Web of Science ®Google Scholar
• Jiang X, Chen X, Jaiprasart P, Carpenter TJ, Zhou R, Wang W. Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans. Eur J Pharm Sci. 2020;146:105260. doi:10.1016/j.ejps.2020.105260.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J Immunother Cancer. 2018;6(1). doi:10.1186/s40425-018-0343-9.
   PubMedGoogle Scholar
• Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, Wu T, Chen D, Chang AH, Gao Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10(2):20–23. doi:10.1038/s41408-020-0280-y.
   PubMed Web of Science ®Google Scholar
• Sun Z, De Xun R, Liu MS, Wu XQ, Qu HT. The association between glucocorticoid administration and the risk of impaired efficacy of axicabtagene ciloleucel treatment: a systematic review. Front Immunol. 2021;12(April):1–8. doi:10.3389/fimmu.2021.646450.
   Google Scholar
• Nägele V, Kratzer A, Zugmaier G, Holland C, Hijazi Y, Topp MS, Gökbuget N, Baeuerle PA, Kufer P, Wolf A, et al. Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Exp Hematol Oncol. 2017;6(1):1–14. doi:10.1186/s40164-017-0074-5.
   PubMedGoogle Scholar
• Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, Luke JJ, Butler MO, Stanhope S, Collins L, et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J Clin Oncol. 2022;40(17):1939–48. doi:10.1200/JCO.21.01805.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Sehn LH, Assouline SE, Bosch F, Magid Diefenbach CS, Flinn I, Hong J, Kim WS, Matasar MJ, Nastoupil LJ, et al. Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol. 2019;37(15_suppl):7518–7518. doi:10.1200/JCO.2019.37.15_suppl.7518.
   Web of Science ®Google Scholar
• Liu JF, O’Malley DM. Phase 1/2 study of REGN4018, a MUC16 x CD3 bispecific antibody, as monotherapy or in combination with cemiplimab in patients with recurrent ovarian cancer. SGO 2021; Virtual meeting. Poster 10818.
   Google Scholar
• Ravandi F, Bashey A, Stock W, Foran JM, Mawad R, Egan D, Blum W, Yang A, Pastore A, Johnson C, et al. Complete responses in relapsed/refractory Acute Myeloid Leukemia (AML) patients on a weekly dosing schedule of vibecotamab (XmAb14045), a CD123 x CD3 T cell-engaging bispecific antibody; initial results of a phase 1 study. Blood. 2020;136(Supplement 1):4–5. doi:10.1182/blood-2020-134746.
   PubMed Web of Science ®Google Scholar
• Patel K, Michot J-M, Chanan-Khan A, Ghesquieres H, Bouabdallah K, Byrd JC, Cartron G, Portell CA, Solh M, Tilly H, et al. Safety and anti-tumor activity of plamotamab (XmAb13676), an anti-CD20 x anti-CD3 bispecific antibody, in subjects with relapsed/refractory non-hodgkin’s lymphoma. Blood. 2021;138(Supplement 1):2494–2494. doi:10.1182/blood-2021-144350.
   Google Scholar
• Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665–74. doi:10.1016/S0140-6736(21)01338-6.
   PubMed Web of Science ®Google Scholar
• Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle PA, Kufer P, Wolf A, Nagorsen D, Zhu M. Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-hodgkin lymphoma. Curr Clin Pharmacol. 2018;13(1):55–64. doi:10.2174/1574884713666180518102514.
   PubMed Web of Science ®Google Scholar
• Hosseini I, Gadkar K, Stefanich E, Li CC, Sun LL, Chu YW, Ramanujan S. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. Npj Syst Biol Appl. 2020;6(1). doi:10.1038/s41540-020-00145-7.
   PubMed Web of Science ®Google Scholar
• Chen X, Kamperschroer C, Wong G, Xuan D. A modeling framework to characterize cytokine release upon T-cell–engaging bispecific antibody treatment: methodology and opportunities. Clin Transl Sci. 2019;12(6):600–08. doi:10.1111/cts.12662.
   PubMedGoogle Scholar
• El-Rayes B, Hendifar AE, Pant S, Wilky BA, Reilley M, Benson AB, Chow WA, Konda B, Starr J, Ahn DH, et al. Preliminary safety, pharmacodynamic, and antitumor activity of tidutamab, an SSTR2 x CD3 bispecific antibody, in subjects with advanced neuroendocrine tumors. Presented at: 2021 NANETS Annual Symposium; November 3–6, 2021; Virtual meeting. Abstract 109.
   Google Scholar
• Bartlett NL, Giri P, Budde LE, Schuster SJ, Assouline S, Matasar MJ, Yoon -S-S, Canales M, Gutierrez NC, Fay K, et al. Subcutaneous (SC) administration of mosunetuzumab with cycle 1 step-up dosing is tolerable and active in patients with relapsed/refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): initial results from a phase I/II study. Blood. 2021;138(Supplement 1):3573–3573. doi:10.1182/blood-2021-147937.
   Google Scholar
• Nooka AK, Moreau P, Usmani SZ, Garfall AL, van de Donk NWCJ, San-Miguel JF, Oriol Rocafiguera A, Chari A, Karlin L, Mateos M-V, et al. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): updated efficacy and safety results from MajesTEC-1. J Clin Oncol. 2022;40(16_suppl):8007–8007. doi:10.1200/JCO.2022.40.16_suppl.8007.
   Web of Science ®Google Scholar
• Minnema MC, Krishnan AY, Berdeja JG, Oriol Rocafiguera A, van de Donk NWCJ, Rodríguez-Otero P, Morillo D, Mateos M-V, Costa LJ, Caers J, et al. Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): updated results from MonumenTAL-1. J Clin Oncol. 2022;40(16_suppl):8015–8015. doi:10.1200/JCO.2022.40.16_suppl.8015.
   Web of Science ®Google Scholar
• Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;1–11. doi:10.1056/nejmoa2203478.
   Google Scholar
• Li Z, Yu X, Li Y, Verma A, Chang HP, Shah DK. A two-pore physiologically based pharmacokinetic model to predict subcutaneously administered different-size antibody/antibody fragments. AAPS J. 2021;23(3):62. doi:10.1208/s12248-021-00588-8.
   PubMed Web of Science ®Google Scholar
• Sánchez-Félix M, Burke M, Chen HH, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. Adv Drug Deliv Rev. 2020;167:66–77. doi:10.1016/j.addr.2020.05.009.
   PubMed Web of Science ®Google Scholar
• Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu D, Zepeda M, Jawa V. Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. J Pharm Sci. 2017;106(10):2946–54. doi:10.1016/j.xphs.2017.05.030.
   PubMed Web of Science ®Google Scholar
• Lim EA, Schweizer MT, Chi KN, Aggarwal RR, Agarwal N, Gulley JL, Attiyeh EF, Greger J, Wu S, Jaiprasart P, et al. Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(6_suppl):279–279. doi:10.1200/JCO.2022.40.6_suppl.279.
   Web of Science ®Google Scholar
• Shah M, Rahman A, Theoret MR, Pazdur R. The drug-dosing conundrum in oncology — when less is more. N Engl J Med. 2021;385(16):1445–47. doi:10.1056/NEJMp2109826.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Ahn M-J, Akamatsu H, Blackhall FH, Borghaei H, Hummel H-D, Johnson ML, Reck M, Zhang Y, Jandial D, et al. Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE)immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC). J Clin Oncol. 2022;40(16_suppl):8603–8603. doi:10.1200/JCO.2022.40.16_suppl.TPS8603.
   Web of Science ®Google Scholar
• Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, Lesokhin A, Forsberg PA, Laubach JP, Costa LJ, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated Relapsed/Refractory Multiple Myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138(Supplement 1):157–157. doi:10.1182/blood-2021-147983.
   Google Scholar
• Li T, Hiemstra IH, Chiu C, Oliveri RS, Elliott B, DeMarco D, Salcedo T, Egerod FL, Sasser K, Ahmadi T, et al. Semimechanistic physiologically‐based pharmacokinetic/pharmacodynamic model informing epcoritamab dose selection for patients with <scp>B‐Cell&#x003C;/scp> lymphomas. Clin Pharmacol Ther. 2022;112(5):1108–19. doi:10.1002/cpt.2729.
   PubMed Web of Science ®Google Scholar
• Bröske A-ME, Korfi K, Belousov A, Wilson S, Ooi C-H, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-hodgkin lymphoma. Blood Adv. 2022;6(3):1025–37. doi:10.1182/bloodadvances.2021005954.
   PubMed Web of Science ®Google Scholar
• Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, Evans TRJ, Anthoney A, Shoushtari AN, Hamid O, et al. Tebentafusp, A TCR/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020;26(22):5869–78. doi:10.1158/1078-0432.CCR-20-1247.
   PubMed Web of Science ®Google Scholar
• Ma H, Wang H, Sove RJ, Jafarnejad M, Tsai CH, Wang J, Giragossian C, Popel AS. A quantitative systems pharmacology model of T cell engager applied to solid tumor. AAPS J. 2020;22(4):1–16. doi:10.1208/s12248-020-00450-3.
   Web of Science ®Google Scholar
• Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357–62. doi:10.1016/j.csbj.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Kang C. Mosunetuzumab: first approval. Drugs. 2022;0123456789:1–6. doi:10.1007/s40265-022-01749-5.
   Google Scholar
• Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, Rasche L, Hartmann E, Dandekar T, Einsele H, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31(10):2181–90. doi:10.1038/leu.2017.41.
   PubMed Web of Science ®Google Scholar
• Catakovic K, Klieser E, Neureiter D, Geisberger R. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal. 2017;15(1):1. doi:10.1186/s12964-016-0160-z.
   PubMed Web of Science ®Google Scholar
• Kobold S, Pantelyushin S, Rataj F, Vom Berg J. Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy. Front Oncol. 2018:8. doi:10.3389/fonc.2018.00285.
   PubMed Web of Science ®Google Scholar
• Sam J, Colombetti S, Fauti T, Roller A, Biehl M, Fahrni L, Nicolini V, Perro M, Nayak T, Bommer E, et al. Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity. Front Oncol. 2020;10. doi:10.3389/fonc.2020.575737.
   PubMed Web of Science ®Google Scholar
• Ma H, Wang H, Sové RJ, Wang J, Giragossian C, Popel AS. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. J Immunother Cancer. 2020;8(2):1–11. doi:10.1136/jitc-2020-001141.
   Web of Science ®Google Scholar
• Sánchez J, Nicolini V, Fahrni L, Waldhauer I, Walz A-C, Jamois C, Fowler S, Simon S, Klein C, Umaña P, et al. Preclinical InVivo data integrated in a modeling network informs a refined clinical strategy for a CD3 T-cell bispecific in combination with anti-PD-L1. AAPS J. 2022;24(6):106. doi:10.1208/s12248-022-00755-5.
   PubMed Web of Science ®Google Scholar
• Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019;11(496). doi:10.1126/scitranslmed.aav5989
   PubMed Web of Science ®Google Scholar
• Herter S, Sam J, Ferrara Koller C, Diggelmann S, Bommer E, Schönle A, Claus C, Bacac M, Klein C, Umana P. RG6076 (CD19-4-1BBL): CD19-targeted 4-1BB ligand combination with glofitamab as an off-the-shelf, enhanced T-cell redirection therapy for B-cell malignancies. Blood. 2020;136(Supplement 1):40–40. doi:10.1182/blood-2020-134782.
   Google Scholar
• Winer IS, Shields AF, Yeku OO, Liu JF, Peterman MJ, Yoo SY, Lowy I, Yama-Dang NA, Goncalves PH, Kroog G. A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA). J Clin Oncol. 2021;39(15_suppl):5602–5602. doi:10.1200/JCO.2021.39.15_suppl.TPS5602.
   Web of Science ®Google Scholar
• Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease–drug–drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735–40. doi:10.1038/clpt.2011.35.
   PubMed Web of Science ®Google Scholar
• Xu Y, Hijazi Y, Wolf A, Wu B, Sun Y, Zhu M. Physiologically based pharmacokinetic model to assess the influence of blinatumomab-mediated cytokine elevations on cytochrome P450 enzyme activity. CPT Pharmacometrics Syst Pharmacol. 2015;4(9):507–15. doi:10.1002/psp4.12003.
   PubMedGoogle Scholar
• Budde LE, Ghosh N, Chavez JC, Lossos IS, Mehta A, Dorritie KA, Kamdar MK, Negricea R, Pham S, Hristopoulos M, et al. Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL). J Clin Oncol. 2021;39(15_suppl):7520–7520. doi:10.1200/JCO.2021.39.15_suppl.7520.
   Web of Science ®Google Scholar
• Weddell J. Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors. CPT Pharmacom & Syst Pharma. 2023; Early View. doi:10.1002/psp4.12928.
   Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–80. doi:10.1038/s41568-020-0285-7.
   PubMed Web of Science ®Google Scholar
• Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, Cortez-Retamozo V, Ospina B, Posternak V, Ulinski G, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer. 2020;1(1):86–98. doi:10.1038/s43018-019-0004-z.
   PubMedGoogle Scholar
• Abrams RE, Pierre K, Murr NE, Seung E, Wu L, Luna E, Mehta R, Li J, et al. Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma. Sci Rep. 2022;12(1):10976. doi:10.1038/s41598-022-14726-5.
   PubMed Web of Science ®Google Scholar
• Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, et al. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood. 2018;132(23):2484–94. doi:10.1182/blood-2018-05-849802.
   PubMed Web of Science ®Google Scholar
• Passariello M, Yoshioka A, Takahashi K, Hashimoto S, Rapuano Lembo R, Manna L, Nakamura K, De Lorenzo C. Novel bi-specific immuno-modulatory tribodies potentiate T cell activation and increase anti-tumor efficacy. Int J Mol Sci. 2022;23(7):3466. doi:10.3390/ijms23073466.
   PubMed Web of Science ®Google Scholar
• Dicara DM, Bhakta S, Go MA, Ziai J, Firestein R, Forrest B, Gu C, Leong SR, Lee G, Yu S-F, et al. Development of T-cell engagers selective for cells co-expressing two antigens. MAbs. 2022;14(1). doi:10.1080/19420862.2022.2115213
   PubMed Web of Science ®Google Scholar
• Panchal A, Seto P, Wall R, Hillier BJ, Zhu Y, Krakow J, Datt A, Pongo E, Bagheri A, Chen THT, et al. COBRA™: a highly potent conditionally active T cell engager engineered for the treaTMent of solid tumors. MAbs. 2020;12(1):1792130. doi:10.1080/19420862.2020.1792130.
   PubMed Web of Science ®Google Scholar
• Boustany LM, LaPorte SL, Wong L, White C, Vinod V, Shen J, Yu W, Koditek D, Winter MB, Moore S, et al. A Probody T Cell–engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity. Cancer Res. 2022;82(22):4288–98. doi:10.1158/0008-5472.CAN-21-2483.
   PubMed Web of Science ®Google Scholar
• Stroh M, Sagert J, Burke JM, Apgar JF, Lin L, Millard BL, Kavanaugh WM. Quantitative systems pharmacology model of a masked, tumor-activated antibody. CPT Pharmacometrics Syst Pharmacol. 2019;8(9):676–84. doi:10.1002/psp4.12448.
   PubMedGoogle Scholar